These joint publications illustrate the utility of Crown Bioscience’s proprietary FATZO model as a model for obesity and type 2 diabetes in preclinical studies.
Selexis to Develop High-performance Research Cell Banks to Expedite the Manufacturing of Immunotherapy Clinical Candidates Designed to Target Cancers of High Unmet Need
Second and Third Commercial License Agreements Between the Partners Underscore the Advantages of Selexis’ SUREtechnology Platform™, Aids OSE Immunotherapeutics Candidates’ Advancement into Clinic
Paper in Biotechnology and Bioengineering describes faster and more efficient technology for isolation of high-production CHO cell lines for use in manufacturing biologics
The data derived from studies using CrownBio’s portfolio showed the immunotherapy’s potential clinical utility and demonstrated the benefits of using CrownBio’s platform in preclinical efficacy tes...
CrownBio will add a significant number of cell lines and reference standards related to EGFR, KRAS, and BRAF signaling cascades of the MAPK pathway, which plays a critical role in the development a...
“The publication of these papers are indicative of how CrownBio continues to further validate the translatability of this model and our commitment to bring to the market novel models that are more ...
Researchers at JAX will immediately begin leveraging CrownBio’s vast research services in oncology and CVMD to generate new insights into therapeutic approaches to target disease.
